

ARC MEDICAL EXPANDS OFFICE SPACE

ARC Medical, Inc.

TUCKER, GA, SEPTEMBER 7, 2007: ARC Medical announces a move to a larger facility. Effective 28 September 2007 ARC will move to 4296 Cowan Road Tucker, GA 30084. Phone, Fax, e-mail, voice mail and Internet contacts will not change. Continued growth in the company's core business in the ICU and anesthesia markets necessitated more than tripling the office and warehouse space for the company. ARC's products include ThermoFlo™ for ICU humidification, circuitGuard™ for Anesthesia Circuit Protection, and SLIPA™, the cuffless supra-glottic airway.

SLEEPMATE TECHNOLOGIES® RECEIVES ACCREDITATION AS A-STEP PROVIDER



Midlothian, VA, July 23, 2007 – Sleepmate Technologies® recently received accreditation from the American Academy of Sleep Medicine (AASM) as a Provider of the Accredited Sleep Technologist Education Program, A-STEP.

A-STEP provides participants with standardized education and training that develops a knowledge-base about sleep medicine and the professional skills required of a sleep technologist. As a staff member at a sleep facility, a sleep technologist administers sleep tests to patients as well as therapeutic services. The sleep technologist also assists the sleep physician with patient care and education.

A-STEP is a two-step training program that includes an 80-hour educational course (STEP 1) and an 18-month on-the-job training and e-learning program (STEP 2). Sleepmate Technologies has earned a two-year accreditation as an A-STEP Provider, meaning that the education offered by Sleepmate Technologies, STEP 1 course has met the standards of accreditation designated by the AASM. The accreditation process involved a detailed evaluation of Sleepmate Technologies program, including faculty, curriculum, resources and assessment.

"The American Academy of Sleep Medicine congratulates Sleepmate Technologies on fulfilling the high standards required for receiving accreditation as an A-STEP Provider," said Alejandro D. Chediak, MD, AASM president. "Sleepmate Technologies A-STEP is a significant resource to the local community as it ensures that those who assist in the diagnosis and treatment of patients with sleep disorders are well-trained and that patients suffering from sleep disorders receive the highest quality of care."

Individuals interested in receiving formalized education and training in sleep technology by enrolling as an A-STEP participant at Sleepmate Technologies can contact our customer support by telephone at 804-378-8265.

MAQUET, INC. WELCOMES NEW VICE PRESIDENT OF CRITICAL CARE SALES

MAQUET

BRIDGEWATER, NJ (September 20, 2007) – MAQUET, a leading developer, manufacturer and distributor of innovative medical devices – has announced the appointment of Steven Greenfield as Vice President of Critical Care Sales. Greenfield will be responsible for managing the critical care division's U.S. organization of sales representatives.

"We are pleased that Steve has joined the MAQUET team and look forward to his contributions that will drive our continued success and future growth," said President and CEO David DeSantis, "Steve's knowledge and expertise will strengthen the evolution of our growing company and our commitment to the respiratory care community."

Greenfield began his career as a Registered Respiratory Therapist and worked his way up to department director. He brings over 20 years experience in sales and management in which he has distinguished himself in many leadership roles at world-class companies such as Baxter, Stryker and most recently Johnson & Johnson.

"I am excited to join the MAQUET team and look forward to working with its customers, representatives and employees. MAQUET has a very strong organization that is customer focused and committed to providing superior products and services," said Greenfield.

RESMED NAMES KIERAN GALLAHUE AS CHIEF EXECUTIVE OFFICER, EFFECTIVE JANUARY 1, 2008. DR. PETER FARRELL TO REMAIN CHAIRMAN OF THE BOARD



ResMed Inc. (NYSE:RMD) announced that its board of directors has unanimously approved a succession plan for executive management of the company. Effective January 1, 2008, Kieran T. Gallahue will be promoted to Chief Executive Officer and will join the board of directors. Mr. Gallahue, 44, will succeed Dr. Peter C. Farrell, 65. As of January 1, 2008, Dr. Farrell will relinquish his position as CEO, but will continue serving as Executive Chairman of the Board until June 30, 2008, when he will become non-executive Chairman.

"Since joining ResMed in 2003, Kieran has demonstrated strong leadership qualities," said Dr. Farrell. "He has been instrumental in improving our operational execution, targeting our research and development efforts, focusing our commercial teams to better serve patients and customers, while strengthening the depth of our management. He has earned the respect of our employees and customers. He has the full support of myself and the Board, and is the right person to succeed me as ResMed's Chief Executive Officer."

"Since founding the company in 1989, I have been passionate about the need to increase awareness of sleep-disordered breathing among both the public and the medical community, as well as the need to increase understanding of the deleterious consequences of the disease if left untreated," Dr. Farrell continued. "As Chairman, I intend to remain significantly engaged in the Company's mission and strategy."

"It is an honor and a privilege to build on the solid foundation of this Company established by one of the industry's true visionaries," said Gallahue. "I am excited about the opportunities ahead of us -- a vast untapped market, market-leading technology, and a world class team of employees. I appreciate having the confidence of Peter and the Board and look forward to leading the global team to continued success."

Gallahue joined ResMed in January 2003 as President and Chief Operating Officer of the Americas. He was named President and Chief Operating Officer - ResMed Global, in September 2004. Before joining ResMed, Mr. Gallahue served as President of Nanogen, Inc., a San Diego-based DNA research and medical diagnostics company. In his earlier career, he also worked for Instrumentation Laboratory, Procter & Gamble and the General Electric Company. Mr. Gallahue holds a BA degree from Rutgers University and an MBA from Harvard Business School.

TELEFLEX TO ACQUIRE ARROW INTERNATIONAL IN \$2.0 BILLION TRANSACTION

**Teleflex
MEDICAL**

Teleflex Incorporated, (NYSE : TFX) a diversified company with an expanding medical technology business and Arrow International, Inc. (NASDAQ : ARRO), a leading global provider of catheter-based access and therapeutic products for critical and cardiac care, announced today that they have entered into a definitive agreement pursuant to which Teleflex will acquire Arrow in an all cash transaction valued at approximately \$2 billion.

The merger agreement, which was unanimously approved by both companies' Boards of Directors, provides for a cash payment of \$45.50 per share for each outstanding share of Arrow stock, representing a premium of 20 percent over Arrow's closing share price on July 20, 2007.

"With the execution of this merger agreement, Teleflex is redefining its portfolio and its Medical Segment by creating a \$1.4 billion medical technology business that will be the largest source of the company's revenues and profitability," said Jeffrey P. Black, Chairman of the Board and Chief Executive Officer of Teleflex. "With the addition of Arrow, we expect that by fiscal 2008 the Medical Segment should achieve annual revenues of approximately \$1.5 billion and generate operating margins in the 20 percent range. We expect the transaction to be meaningfully accretive to Teleflex's earnings by 2009."